MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,303K
EPS
-$0.08
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
Restructuring charges
-
4,527
Research and development
1,247
10,537
General and administrative
1,919
1,817
Total operating expenses
3,166
16,881
Loss from operations
-3,166
-16,881
Interest income
123
246
Interest expense
10
7
Australian research and development incentives
-56
1
Foreign currency gain (loss)
8
-2
Loss before income taxes
-3,101
-
Provision for income taxes
202
-
Net loss
-3,303
-16,643
Net loss attributable to common stockholders
-3,303
-16,643
Basic EPS
-0.08
-0.4
Diluted EPS
-0.08
-0.4
Basic Average Shares
41,444,979
41,444,979
Diluted Average Shares
41,444,979
41,444,979
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$3,303K
Net loss
-$3,303K
Loss before income
taxes
-$3,101K
Provision for income taxes
$202K
Interest income
$123K
Foreign currency gain
(loss)
$8K
Loss from operations
-$3,166K
Australian research and
development incentives
-$56K
Interest expense
$10K
Total operating
expenses
$3,166K
General and
administrative
$1,919K
Research and development
$1,247K
Buy us a coffee
LEAP THERAPEUTICS, INC. (LPTX)
LEAP THERAPEUTICS, INC. (LPTX)